How to save $25 billion and more on drug costs
Patent settlements bring cheaper generics to market early and cut healthcare spending
A patent triumph of public interest
New flexibilities make public interest safeguards integral to drug patent rights
Strong medicine for weak drug patents
Revocation of Pfizer, Roche patents for lacking inventive step signals healthy trend
Japanese biopiracy of our Ballia barley
Japan’s Sapporo brewery patents Indian barley gene without giving benefit to farmers
Left sees red over Marx copyright
A small publisher of Collected Works has run afoul of Marxists by asserting copyright
Rotten tomato for Monsanto
US biotech giant's claim on a natural tomato is its latest patent to be revoked by Europe after soy and wheat
Crazy for GI? Think again
The protection of Geographical Indication is not a guarantee that the artisan or producer will benefit; traders can corner the premium
A rather ridiculous gap
Clothing giant Gap’s trademark infringement notice to an NGO selling products made from recycled waste is a curious case
India’s 3 D Message
The Supreme Court judgment in the Novartis case clearly upholds India’s patent laws, not weakens the patent regime
The fine line for judges
Judges have recused themselves in a number of cases but there are no clear guidelines on what constitutes conflict of interest
Pushing limits of drug access
Relying solely on gross national income to determine priorities in global health is not working any more
NCD battle starts now
The UN agreement on non-communicable diseases will get snagged on the issue of intellectual property rights for drugs
Bitter ABS medicine for AYUSH
Manufacturers cry foul as they receive notices from state boards to pay royalty
Maths of Gilead's hepatitis C drug
Why US firm's super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price
Yale guide to fighting drug patent barriers
How human rights can be used to challenge oppressive intellectual property laws
Evergreen Novartis
The Swiss pharma giant’s challenge to India’s patent law, now in the Supreme Court, may help define drug efficacy
Annihilation of caste and copyright claims
Ambedkar’s works have been published widely and yet pose a copyright conundrum
Cipla's audacious move
Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug
Monsanto does it again
The biotech seed giant sues a farmer for planting unbranded commodity seeds bought in the open market for patent infringement
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
Righting the copywrong
Amending the Copyright Act to give directors, composers and musicians rights over their work has corrected a historic wrong but trouble is brewing
Patent hypocrisies of US
American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards
Any cheers for Doha pact?
The Doha Declaration on protecting public health is a decade old, but developing countries have not been able to make use of TRIPs flexibilities
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
No climate for cleantech
Most of the clean energy innovations are with just six rich countries and hardly any technology is coming to developing nations
.jpg "Strong medicine for weak drug patents")
.jpg "A rather ridiculous gap")
.jpg "The fine line for judges")
.jpg "NCD battle starts now")
.jpg "Yale guide to fighting drug patent barriers")
.jpg "The natco-pfizer test")
.jpg "Patent hypocrisies of US")
